Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Treasury Shares (2019 - 2025)

X4 Pharmaceuticals' Treasury Shares history spans 7 years, with the latest figure at $73381.0 for Q4 2025.

  • For Q4 2025, Treasury Shares fell 63.12% year-over-year to $73381.0; the TTM value through Dec 2025 reached $73381.0, down 63.12%, while the annual FY2025 figure was $73381.0, 63.12% down from the prior year.
  • Treasury Shares reached $73381.0 in Q4 2025 per XFOR's latest filing, down from $99232.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $8.4 million in Q1 2024 to a low of $73381.0 in Q4 2025.
  • Average Treasury Shares over 5 years is $2.8 million, with a median of $1.5 million recorded in 2022.
  • Peak YoY movement for Treasury Shares: skyrocketed 298.83% in 2023, then tumbled 98.78% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $925101.0 in 2021, then soared by 81.66% to $1.7 million in 2022, then surged by 85.58% to $3.1 million in 2023, then tumbled by 93.62% to $198995.0 in 2024, then crashed by 63.12% to $73381.0 in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Treasury Shares are $73381.0 (Q4 2025), $99232.0 (Q3 2025), and $333264.0 (Q2 2025).